

Paradigm Shifts and Improving Outcomes for Patients with dMMR/MSI-H Endometrial Cancer

Friday, 21 June | 13:15–14:15 (CEST)

Auditorium, Palazzo dei Congressi
of the Firenze Fiera, Florence



Chair

Dr Sandro Pignata, MD, PhD

Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy

- Recent data on survival outcomes from anti-PD-(L)1 trials in primary advanced/recurrent endometrial cancer



Prof Christian Marth, MD, PhD

Medical University of Innsbruck, Austria

- Importance of biomarkers and optimal safety management to improve patient outcomes



Ms Andreia Fernandes, MSc

The Royal Marsden NHS Foundation Trust, London, UK

- Panel moderator

GSK Scientific Material. This material does not have advertising purposes, it is not transmitted and/or disseminated by the GSK Sales Representatives and, therefore, it is not subject to the provisions of Title VIII (Advertising) of Legislative Decree 219/06.

Scientific dissemination is based on published and accessible data and has an informative/educational purpose. To this end, the data is presented faithfully reflecting scientific publications without any modification or addition. Its content is protected by copyright and may not be reproduced (photo, recording or "screen prints"), disclosed or transmitted to any third party by any means, without written authorization of GSK. We remind you that you are in a scientific environment aimed at health professionals and that it is not allowed to spread promotional messages to general public. Therefore, please do not include the content of the meeting in your social media posts related to this meeting.

Organised and sponsored by GSK | For Healthcare Professionals only | NX-GBL-DST-WCNT-240004 01/05/2024

GSK